Catalyst Q2 revenue $99.6M, GAAP EPS $0.33 (vs $0.20), raises FY2023 guide to $380M-$390M

CATALYST PHARMACEUTICALS, INC.

2023-Q2 EPS reported $0.59 revenue$184,948,000

Q2 net product revenue $99.5M: FIRDAPSE $64.9M (+22% YoY); FYCOMPA $34.6M first-time contribution.
GAAP net income $37.8M, diluted EPS $0.33; Non-GAAP net income $60.4M, diluted EPS $0.53.
Raised FY2023 total revenue guidance to $380M-$390M.
Closed acquisition of North American vamorolone license for $75M in July; $15M Santhera equity investment and $10M Ruzurgi installment paid post-Q2.
Submitted sNDA for FIRDAPSE to increase maximum indicated dose to 100 mg/day.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.